273 related articles for article (PubMed ID: 2475847)
41. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
[TBL] [Abstract][Full Text] [Related]
42. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged.
Jenkins D; Jones RT; Clarke AM
Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330
[TBL] [Abstract][Full Text] [Related]
43. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
44. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
45. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
Bauer HW
Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908
[TBL] [Abstract][Full Text] [Related]
46. Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients.
Passadakis P; Ersoy F; Tam P; Memmos D; Siamopoulos K; Ozener C; Akçiçek F; Camsari T; Ates K; Ataman R; Vlachojannis J; Dombros N; Utas C; Akpolat T; Bozfakioglu S; Wu GG; Karayaylali I; Arinsoy T; Stathakis C; Yavuz M; Tsakiris D; Dimitriades A; Yilmaz ME; Gültekin M; Karayalçin B; Challa A; Polat N; Oreopoulos DG
Adv Perit Dial; 2004; 20():203-8. PubMed ID: 15384827
[TBL] [Abstract][Full Text] [Related]
47. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
48. Carcinoma of the prostate. Serum tumour markers.
Ekman P
Scand J Urol Nephrol Suppl; 1991; 139():15-8. PubMed ID: 1722588
[TBL] [Abstract][Full Text] [Related]
49. [The importance of tumor markers in adenocarcinoma of the prostate].
Sampalmieri G; Giancola FL; Cabras A
Riv Eur Sci Med Farmacol; 1992; 14(2):139-42. PubMed ID: 1484986
[TBL] [Abstract][Full Text] [Related]
50. [Tumor markers in prostate cancer].
Kuriyama M
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999
[TBL] [Abstract][Full Text] [Related]
51. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
52. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
53. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
[TBL] [Abstract][Full Text] [Related]
54. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
Cohen RJ; Glezerson G; Haffejee Z
Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
[TBL] [Abstract][Full Text] [Related]
55. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
Mai KT; Yazdi HM; Farmer J
Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
[TBL] [Abstract][Full Text] [Related]
56. PSA and PAP as immunohistochemical markers in prostate cancer.
Epstein JI
Urol Clin North Am; 1993 Nov; 20(4):757-70. PubMed ID: 7505984
[TBL] [Abstract][Full Text] [Related]
57. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
58. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
59. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
60. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
